3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
39
Recruiting
13
Terminated
7
Unknown
5
Active not recruiting
5
Withdrawn
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
105
Gastrointestinal
12
Thoracic
8
Breast
8
Head & Neck
5
Genitourinary
5
CNS
3
Sarcoma
2
Plasma cell
2
Other solid neoplasm
2
Dermatologic
2
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Endocrine
1
Conditions
Leukemia, Myeloid, Acute
139
Precursor Cell Lymphoblastic Leukemia-Lymphoma
66
Hematologic Neoplasms
64
Leukemia
37
Leukemia, Lymphocytic, Chronic, B-Cell
35
Recurrence
24
Myelodysplastic Syndromes
23
Lymphoma
23
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
16
Neoplasms
12
Multiple Myeloma
11
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Neoplasm, Residual
8
Motor Activity
8
Lymphoma, Non-Hodgkin
8
Lymphoma, Follicular
8
Lymphoma, Mantle-Cell
7
Lymphoma, B-Cell
7
Leukemia, B-Cell
7
Myeloproliferative Disorders
5
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, B-Cell, Marginal Zone
5
Leukemia, Plasma Cell
5
Leukemia, Myeloid, Chronic-Phase
5
Febrile Neutropenia
5
Burkitt Lymphoma
5
Waldenstrom Macroglobulinemia
4
Primary Myelofibrosis
4
Pain
4
Neoplasm Metastasis
4
Interventions
trametinib
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Ovarian Neoplasms
×
Other hematologic neoplasm
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled